Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 16/20 | 0.62 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.55 |
| ▸ | MUSK | O15146 | 1/20 | 0.55 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.55 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.55 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.55 |
| ▸ | PAK3 | O75914 | 1/20 | 0.55 |
| ▸ | STK10 | O94804 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | CSF1R | P07333 | 1/20 | 0.55 |
| ▸ | YES1 | P07947 | 1/20 | 0.55 |
| ▸ | LYN | P07948 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73428 | 0.93 | FLT3 (0.62) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL28416088 | 0.90 | FLT3 (0.61) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL74010 | 0.87 | FLT3 (0.64) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL474761 | 0.83 | FLT3 (0.73) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL75114 | 0.83 | FLT3 (0.58) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Hydrochloric Acid SCHEMBL18409101 | 0.83 | FLT3 (0.72) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL15079640 | 0.82 | FLT3 (0.56) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL73882 | 0.80 | KMT2A (0.46) | FLT3ALDH1A1KDM4ESMN1; SMN2MAPT | |
| SCHEMBL74009 | 0.80 | FLT3 (0.65) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL13354829 | 0.79 | FLT3 (0.64) | FLT3KDRBMPR1BMUSKEPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150612-A1 | PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES | Ambit Biosciences Corporation (US) | 2017-04-05 | — | — | EP | claimed |
| EP-3125920-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | Del Mar Pharmaceuticals (CA) | 2017-02-08 | — | — | EP | claimed |
| EP-2496584-B1 | PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES | AMBIT BIOSCIENCES CORP (US) | 2016-09-21 | — | — | EP | claimed |
| US-9284332-B2 | Process for the preparation of imidazo[2,1-B][1,3]benzothiazole derivatives | AMBIT BIOSCIENCES CORPORATION (US) | 2016-03-15 | — | — | US | claimed |
| WO-2015154064-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2015-10-08 | — | — | WO | claimed |
| US-8921546-B2 | Imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCES CORPORATION (US) | 2014-12-30 | — | — | US | claimed |
| US-20140243525-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION (US) | 2014-08-28 | — | — | US | claimed |
| US-20130005966-A1 | PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES | AMBIT BIOSCIENCES CORP. (US) | 2013-01-03 | — | — | US | claimed |
| EP-2496584-A1 | PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES | Ambit Biosciences Corp. (US) | 2012-09-12 | — | — | EP | claimed |
| WO-2011056939-A1 | PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES | AMBIT BIOSCIENCES CORP. (US) | 2011-05-12 | — | — | WO | claimed |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2023-01-03 | — | — | US | disclosed |
| EP-3125920-B1 | DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL OR DIBROMODULCITOL TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2020-12-23 | — | — | EP | disclosed |
| US-20190269646-A9 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2019-09-05 | — | — | US | disclosed |
| US-20180140571-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | BACHA JEFFREY (CA) | 2018-05-24 | — | — | US | disclosed |
| EP-3294284-A1 | COMBINATION OF ANALOGS OR DERIVATIVES OF DIANHYDROGALACTITOL WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT CANCER | Delmar Pharmaceuticals, Inc. (CA) | 2018-03-21 | — | — | EP | disclosed |
| WO-2011056939-A1 | PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES | AMBIT BIOSCIENCES CORP. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20100298313-A1 | METHOD OF USING IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-7820657-B2 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION (US) | 2010-10-26 | — | — | US | disclosed |
| US-20090131426-A1 | SOLID FORMS COMPRISING N-(5-TERT-BUTYL-ISOXAZOL-3-YL)-N'-UREA, COMPOSITIONS THEREOF, AND USES THEREWITH | AMBIT BIOSCIENCES | 2009-05-21 | — | — | US | disclosed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243525-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | FLT3 210/4885KDR 540/4885BMPR1B 2351/4885 |
| US-20100298313-A1 | METHOD OF USING IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK5 | FLT3 363/4885KDR 675/4885BMPR1B 2817/4885 |
| US-20190269646-A9 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DNMT1, MGMT, DCK | FLT3 374/4885KDR 2379/4885BMPR1B 3923/4885 |
| US-20090131426-A1 | SOLID FORMS COMPRISING N-(5-TERT-BUTYL-ISOXAZOL-3-YL)-N'-UREA, COMPOSITIONS THEREOF, AND USES THEREWITH | OAT, TERT, TPMT | FLT3 797/4885KDR 4676/4885BMPR1B 4403/4885 |
| US-20130005966-A1 | PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES | FLT4, FLT1, FLT3 | FLT3 3/4885KDR 13/4885BMPR1B 1133/4885 |
| US-20180140571-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DNMT1, MGMT, DCK | FLT3 374/4885KDR 2379/4885BMPR1B 3923/4885 |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | GRK2, GRK3, BLK | FLT3 128/4885KDR 279/4885BMPR1B 2105/4885 |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DNMT1, MGMT, DCK | FLT3 374/4885KDR 2379/4885BMPR1B 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.